Andrew Lee, MD
Ophthalmology · Houston, TXNPI 1962403105
Payments from drug & device makers
Across 318 payments — averaging $808.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$198K
- AstraZeneca$30K
- Bristol Myers Squibb$9K
- Astrazeneca UK Limited$5K
- Catalyst Pharmaceuticals, Inc.$5K
- Dompe Farmaceutici S.p.a.$5K
- plus $5K from 25 others
What the payments were for
- Consulting fees$30,52812%
- Speaking & faculty fees$192,52775%
- Travel & lodging$25,05510%
- Food & beverage$9,1064%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 212 | $197,631 |
| AstraZeneca(2 entities) | 38 | $30,254 |
| Bristol Myers Squibb | 1 | $9,450 |
| Astrazeneca UK Limited | 3 | $5,102 |
| Catalyst Pharmaceuticals, Inc. | 4 | $4,830 |
| Dompe Farmaceutici S.p.a. | 3 | $4,810 |
| Argenx US, Inc. | 3 | $2,381 |
| Biogen | 1 | $1,000 |
| Dompe US, Inc. | 7 | $360 |
| Alcon | 6 | $275 |
| Sun Pharmaceutical Industries Inc. | 8 | $181 |
| Bausch & Lomb Americas Inc. | 4 | $142 |
| Novartis | 3 | $140 |
| Medtronic | 2 | $120 |
| Penumbra, Inc. | 1 | $74 |
| AbbVie(2 entities) | 3 | $66 |
| UCB, Inc. | 2 | $57 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $55 |
| Stryker | 1 | $48 |
| Shire North American Group Inc | 2 | $42 |
| Genentech USA, Inc. | 1 | $23 |
| Glaukos Corporation | 1 | $22 |
| Kala Pharmaceuticals, Inc. | 1 | $20 |
| Genentech, Inc. | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $18 |
| Eyevance Pharmaceuticals LLC | 1 | $18 |
| Merz North America, Inc. | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Biotissue Holdings Inc. | 1 | $15 |
| Oyster Point Pharma, Inc. | 1 | $15 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPLIZNA$161,683
- ULTOMIRIS$11,410
- TEPEZZA$10,799
- FIRDAPSE$4,700
- VYVGART HYTRULO$2,300
- Oxervate$229
- SOLIRIS$150
- Unity$140
- XIIDRA$109
- PERCEPT PC BRAINSENSE$101
How this compares
$257,216 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Latanoprost | 14 | $94 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Houston
- David BrownHouston$51.7M
- John MichelettiHouston$3.3M
- Michael CaplanHouston$1.4M
- Shaheen KavoussiHouston$1.3M
- Kevin JongHouston$1.2M
- Stephen SladeHouston$1.2M
- Rosa TangHouston$1.1M
- Zaina Al-MohtasebHouston$1.1M
- Fiaz ZamanHouston$1M
- Stephen PflugfelderHouston$788K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.